加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$40.61
+US$0.50 · +1.25%
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
前收盘价
US$40.61
+US$0.50 · +1.25%
盘中时间采用ET。市场数据可能有所延迟。
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
日内区间
当前US$40.61
52周区间
当前US$40.61
盘中时间采用ET。市场数据可能有所延迟。
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
日内区间
当前US$40.61
52周区间
当前US$40.61
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 14.76亿 USD | 15.58亿 USD | 16.63亿 USD | 11.12亿 USD | 11.74亿 USD |
| 销货成本 | 1.96亿 USD | 2.45亿 USD | 2.53亿 USD | 2.18亿 USD | 1.97亿 USD |
| 毛利 | 12.79亿 USD | 13.12亿 USD | 14.1亿 USD | 8.94亿 USD | 9.76亿 USD |
| 研究与开发 | 3.24亿 USD | 2.45亿 USD | 2.71亿 USD | 2.73亿 USD | 2.91亿 USD |
| 销售、一般及管理费用 | 7.15亿 USD | 6.45亿 USD | 6.9亿 USD | 5.91亿 USD | 5.5亿 USD |
| 营业费用 | 10.25亿 USD | 8.92亿 USD | 9.96亿 USD | 9亿 USD | 8.79亿 USD |
| 利息收入 | 4530.4万 USD | 4245万 USD | 3085.4万 USD | 762.9万 USD | 240.8万 USD |
| 利息支出 | 1227.7万 USD | 2257.8万 USD | 2303.2万 USD | 1304万 USD | 1121.9万 USD |
| 折旧和摊销 | 2716.5万 USD | 2853.3万 USD | 7492.7万 USD | 7786.2万 USD | 7865.2万 USD |
| 营业利润 | 2.54亿 USD | 4.21亿 USD | 4.14亿 USD | −608.9万 USD | 9774.6万 USD |
| 净利润 | 2.42亿 USD | 3.67亿 USD | 3.56亿 USD | −1.58亿 USD | −4816.9万 USD |
公司数据更新于 2026年10月11日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
iShares Core S&P Small-Cap ETFIJR4.02亿0.39%1031.91亿 USD0.06%US$137.55+0.17%
Vanguard Morningstar Total Stock Market ETFVTI2.49亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB1.8亿0.10%1853亿 USD0.03%US$289.48+0.64%
iShares Russell 2000 ETFIWM1.77亿0.23%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI1.32亿1.34%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Morningstar Small-Cap Growth ETFVBK1.03亿0.23%447亿 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF9100.43万0.09%954亿 USD0.05%US$235+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT7078.71万2.45%28.91亿 USD0.55%US$265.4+2.00%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
